FHTR
MCID: HYP117
MIFTS: 61

Hypertriglyceridemia (FHTR) malady

Categories: Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hypertriglyceridemia

Aliases & Descriptions for Hypertriglyceridemia:

Name: Hypertriglyceridemia 54 29 52 69
Hypertriglyceridemia, Familial 66 13
Hypertriglyceridemias Familial 52
Fhtr 66

Characteristics:

HPO:

32
hypertriglyceridemia:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 145750
MeSH 42 D006953

Summaries for Hypertriglyceridemia

OMIM : 54 Most individuals with familial hypertriglyceridemia have a hyperlipoproteinemia IV (144600) phenotype. Relatives of... (145750) more...

MalaCards based summary : Hypertriglyceridemia, also known as hypertriglyceridemia, familial, is related to hyperlipoproteinemia type iv and myocardial infarction, and has symptoms including abnormal glucose tolerance, precocious atherosclerosis and increased circulating very-low-density lipoprotein cholesterol. An important gene associated with Hypertriglyceridemia is LIPI (Lipase I), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Metformin and Fenofibrate have been mentioned in the context of this disorder. Affiliated tissues include heart, skin and liver, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

UniProtKB/Swiss-Prot : 66 Hypertriglyceridemia, familial: A common inherited disorder in which the concentration of very low density lipoprotein (VLDL) is elevated in the plasma. This leads to increased risk of heart disease, obesity, and pancreatitis.

Wikipedia : 71 Hypertriglyceridemia denotes high (hyper-) blood levels (-emia) of triglycerides, the most abundant... more...

Related Diseases for Hypertriglyceridemia

Diseases in the Hypertriglyceridemia family:

Hypertriglyceridemia, Transient Infantile

Diseases related to Hypertriglyceridemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
id Related Disease Score Top Affiliating Genes
1 hyperlipoproteinemia type iv 31.5 ADIPOQ APOB COG2 INS
2 myocardial infarction 27.0 ADIPOQ APOA1 APOA2 APOA5 APOB APOC3
3 hypertriglyceridemia, transient infantile 12.3
4 familial lipoprotein lipase deficiency 11.4
5 lipoprotein lipase deficiency 11.1
6 hyperlipidemia, familial combined 10.9
7 lipodystrophy, familial partial, type 4 10.8
8 lipodystrophy, congenital generalized, type 3 10.8
9 lipodystrophy, familial partial, 2 10.8
10 lipodystrophy, congenital generalized, type 1 10.8
11 lipodystrophy, congenital generalized, type 2 10.8
12 diabetes mellitus, noninsulin-dependent, 5 10.7
13 glycogen storage disease ixa 10.7
14 hemophagocytic lymphohistiocytosis, familial, 4 10.7
15 lipodystrophy, congenital generalized, type 4 10.7
16 sea-blue histiocyte disease 10.7
17 glycogen storage disease, type ixa1 10.7
18 hyperlipoproteinemia, type ib 10.7
19 hemophagocytic lymphohistiocytosis, familial, 2 10.7
20 lipodystrophy, familial partial, type 1 10.7
21 diabetes mellitus, noninsulin-dependent 10.7
22 neutral lipid storage disease with myopathy 10.7
23 diabetes mellitus, noninsulin-dependent 1 10.7
24 pancreatitis 10.5
25 acute pancreatitis 10.3
26 obesity 10.3
27 alport syndrome and thin basement membrane nephropathy 10.3 APOE LPL
28 zap-70 deficiency 10.3 APOB APOE
29 polycystic kidney disease, infantile severe, with tuberous sclerosis 10.2 LIPC LPL
30 hepatitis 10.2
31 abducens nerve neoplasm 10.2 APOA5 APOC2 LIPC LPL
32 keratoconus 4 10.2 APOB APOE LDLR
33 dentinogenesis imperfecta type 2 10.1 APOB APOE LDLR
34 mitochondrial complex iii deficiency, nuclear type 4 10.1 APOA1 APOB SLC10A2
35 fetal warfarin syndrome 10.1 APOA1 APOB INS
36 hypercholesterolemia, due to ligand-defective apo b 10.1 APOB APOE LDLR
37 hyperchlorhidrosis, isolated 10.1 APOA1 APOE LIPC LPL
38 c1s deficiency 10.1 APOA5 APOC2 APOE INS LPL
39 primary pigmented nodular adrenocortical disease 10.1 APOA1 APOB APOE INS
40 craniodiaphyseal dysplasia 10.1 APOA1 APOB SERPINE1
41 limb ischemia 10.1 ADIPOQ APOE INS
42 endotheliitis 10.0
43 familial progressive cardiac conduction defect 10.0 APOA1 APOA2 APOE
44 leukemia 10.0
45 diabetic encephalopathy 10.0 ADIPOQ APOE INS
46 atopic dermatitis 4 10.0 APOC3 LPA
47 joint disorders 10.0 APOA1 APOB APOE INS LPL
48 mucopolysaccharidosis iii 10.0 ADIPOQ INS LPL
49 cetp-related hyperalphalipoproteinemia 10.0 APOB APOE INS SERPINE1
50 lymphoblastic leukemia 10.0

Graphical network of the top 20 diseases related to Hypertriglyceridemia:



Diseases related to Hypertriglyceridemia

Symptoms & Phenotypes for Hypertriglyceridemia

Symptoms by clinical synopsis from OMIM:

145750

Clinical features from OMIM:

145750

Human phenotypes related to Hypertriglyceridemia:

32
id Description HPO Frequency HPO Source Accession
1 hypertriglyceridemia 32 HP:0002155
2 abnormal glucose tolerance 32 HP:0001952
3 precocious atherosclerosis 32 HP:0004416
4 increased circulating very-low-density lipoprotein cholesterol 32 HP:0003362
5 atheroeruptive xanthoma 32 HP:0001039

UMLS symptoms related to Hypertriglyceridemia:


hypertriglyceridemic waist

GenomeRNAi Phenotypes related to Hypertriglyceridemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 LDLR LIPC LPA LPL APOA1 APOA5
2 Increased LDL uptake GR00340-A-1 8.92 APOA1 APOE LDLR LPL

MGI Mouse Phenotypes related to Hypertriglyceridemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.06 APOE COG2 GPD1 INS LDLR LIPC
2 growth/size/body region MP:0005378 10.03 LPL SERPINE1 SLC10A2 ADIPOQ APOA2 APOB
3 adipose tissue MP:0005375 9.8 ADIPOQ APOE INS LDLR LPL SERPINE1
4 integument MP:0010771 9.56 ADIPOQ APOA1 APOE INS LDLR LIPI
5 liver/biliary system MP:0005370 9.32 ADIPOQ APOA1 APOB APOE INS LDLR

Drugs & Therapeutics for Hypertriglyceridemia

Drugs for Hypertriglyceridemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
2
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Phase 1 49562-28-9 3339
3
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
4
Amlodipine Approved Phase 4 88150-42-9 2162
5
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-78-2 2244
6
Atenolol Approved Phase 4 29122-68-7 2249
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Doxazosin Approved Phase 4 74191-85-8 3157
9
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
10
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
11
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
12
Ramipril Approved Phase 4 87333-19-5 5362129
13
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
14
Saxagliptin Approved Phase 4 361442-04-8 11243969
15
Liraglutide Approved Phase 4 204656-20-2
16
Pravastatin Approved Phase 4,Phase 3 81093-37-0 54687
17
Fosamprenavir Approved Phase 4,Phase 1,Phase 2 226700-79-4 131536
18
Ritonavir Approved, Investigational Phase 4,Phase 1 155213-67-5 392622
19
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
20
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
21
Chlorpromazine Approved, Vet_approved Phase 4 50-53-3 2726
22
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
23
Haloperidol Approved Phase 4 52-86-8 3559
24
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
25
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
26
Lopinavir Approved Phase 4,Phase 1 192725-17-0 92727
27
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
28
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
29
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
30
Nelfinavir Approved Phase 4 159989-64-7 64143
31
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
32
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
33
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
34
Ezetimibe Approved Phase 4,Phase 3,Phase 2 163222-33-1 150311
35
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
36
Icodextrin Approved, Investigational Phase 4 337376-15-5
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-02-9 14985
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
39
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2 59-67-6 938
40
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 2 98-92-0 936
41 tannic acid Approved, Nutraceutical Phase 4,Phase 3
42
decanoic acid Experimental Phase 4 334-48-5 2969
43 Clofibric Acid Phase 4,Phase 3,Phase 2 882-09-7
44 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
45
Ciprofibrate Phase 4 52214-84-3 2763
46 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Liver Extracts Phase 4,Phase 2,Phase 3
49 Tocopherols Phase 4,Phase 2,Phase 3
50 Tocotrienols Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 334)
id Name Status NCT ID Phase
1 Triglyceride Lowering Study Unknown status NCT00934219 Phase 4
2 Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia Unknown status NCT01480687 Phase 4
3 The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels Unknown status NCT01712867 Phase 4
4 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
5 The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients Unknown status NCT00758927 Phase 4
6 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4
7 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4
8 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4
9 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) Unknown status NCT00712049 Phase 4
10 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4
11 Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol Completed NCT01122355 Phase 4
12 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia Completed NCT00833976 Phase 4
13 Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia Completed NCT02305355 Phase 4
14 Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension Completed NCT00246636 Phase 4
15 Predictors of Response to Fenofibrate Completed NCT01023750 Phase 4
16 Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients Completed NCT00346697 Phase 4
17 A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™ Completed NCT00891293 Phase 4
18 Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects Completed NCT01010399 Phase 4
19 Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate Completed NCT01666041 Phase 4
20 Vascular and Metabolic Effects of Omega-3 Fatty Acids Completed NCT01660932 Phase 4
21 Differential Metabolic Effects of Fenofibrate and Fatty Acid Completed NCT01003847 Phase 4
22 Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients Completed NCT00745407 Phase 4
23 Lovaza® and Microvascular Function in Type 2 Diabetes Completed NCT00931879 Phase 4
24 The Impact of Omega Three Fatty Acids on Vascular Function in HIV Completed NCT01041521 Phase 4
25 Niacin, N-3 Fatty Acids and Insulin Resistance Completed NCT00286234 Phase 4
26 Effects of Omega-3 Fatty Acids on the Human Gene Expression Completed NCT01089231 Phase 4
27 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4
28 A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic Completed NCT01462877 Phase 4
29 Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome Completed NCT01625442 Phase 4
30 Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes Completed NCT02049034 Phase 4
31 Pharmacological Regulation of Fat Transport in Metabolic Syndrome Completed NCT00632840 Phase 4
32 Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation Completed NCT00974272 Phase 4
33 Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients Completed NCT00473655 Phase 4
34 Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment Completed NCT02153879 Phase 4
35 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
36 Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia Completed NCT01052389 Phase 4
37 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4
38 Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r Completed NCT00756730 Phase 4
39 Benefit of Elevation of HDL-C in Women Completed NCT01921010 Phase 4
40 Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome Completed NCT00364221 Phase 4
41 Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women Completed NCT00590629 Phase 4
42 A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Completed NCT00006190 Phase 4
43 Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels Completed NCT00441480 Phase 4
44 Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients Completed NCT00677300 Phase 4
45 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Completed NCT00817843 Phase 4
46 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Recruiting NCT01569724 Phase 4
47 The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN) Recruiting NCT03120299 Phase 4
48 Effects of DPP-4 Inhibition on Triglycerides Recruiting NCT01527747 Phase 4
49 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling Recruiting NCT02437084 Phase 4
50 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Recruiting NCT02721888 Phase 4

Search NIH Clinical Center for Hypertriglyceridemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Hypertriglyceridemia

Genetic tests related to Hypertriglyceridemia:

id Genetic test Affiliating Genes
1 Hypertriglyceridemia 29
2 Hypertriglyceridemia, Familial 24 APOA5 LIPI

Anatomical Context for Hypertriglyceridemia

MalaCards organs/tissues related to Hypertriglyceridemia:

39
Heart, Skin, Liver, Endothelial, Monocytes, Lung, Kidney

Publications for Hypertriglyceridemia

Articles related to Hypertriglyceridemia:

(show top 50) (show all 931)
id Title Authors Year
1
PPAR-I+ Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study. ( 28361462 )
2017
2
Therapeutic plasmapheresis for hypertriglyceridemia-associated acute pancreatitis: case series and review of the literature. ( 28507728 )
2017
3
Severe Hypertriglyceridemia Causing Pancreatitis in a Child with New-onset Type-I Diabetes Mellitus Presenting with Diabetic Ketoacidosis. ( 28400692 )
2017
4
Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. ( 28061854 )
2017
5
LPL gene Pvu II polymorphism and hypertriglyceridemia: a meta-analysis involving 1,640 subjects. ( 28502159 )
2017
6
Light Chain Myeloma induced Severe Hypertriglyceridemia. ( 28511439 )
2017
7
Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated. ( 28487440 )
2017
8
Severe hypertriglyceridemia secondary to venlafaxine use in an older adult on dialysis -case report. ( 28407764 )
2017
9
Hypertriglyceridemia and Pancreatitis-New Evidence That Less Is More-Reply. ( 28460108 )
2017
10
Severe insomnia is associated with hypertriglyceridemia in women with major depression treated in psychiatry settings. ( 28411504 )
2017
11
Severe hypertriglyceridemia during treatment of acute lymphoblastic leukemia associated with type III hyperlipoproteinemia. ( 28371240 )
2017
12
Estrogen-associated severe hypertriglyceridemia with pancreatitis. ( 28391900 )
2017
13
Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing. ( 28391895 )
2017
14
Hypertriglyceridemia, an important and independent risk factor for acute pancreatitis in patients with type 2 diabetes mellitus. ( 28450786 )
2017
15
Extreme hypertriglyceridemia, pseudohyponatremia, and pseudoacidosis in a neonate with lipoprotein lipase deficiency due to segmental uniparental disomy. ( 28438574 )
2017
16
Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents. ( 28440015 )
2017
17
Impact of Hypertriglyceridemia on Carotid Stenosis Progression under Normal Low-Density Lipoprotein Cholesterol Levels. ( 28495179 )
2017
18
Dysbiosis of Intestinal Microbiota and Decreased Antimicrobial Peptide Level in Paneth Cells during Hypertriglyceridemia-Related Acute Necrotizing Pancreatitis in Rats. ( 28522995 )
2017
19
Hypertriglyceridemia and Pancreatitis-New Evidence That Less Is More. ( 28460101 )
2017
20
Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. ( 28402248 )
2017
21
Biochemical mechanism underlying hypertriglyceridemia and hepatic steatosis/hepatomegaly induced by acute schisandrin B treatment in mice. ( 28086886 )
2017
22
Hypertriglyceridemia and Cardiovascular Diseases: Revisited. ( 27014342 )
2016
23
Association between serum cytokine concentrations and the presence of hypertriglyceridemia. ( 27048855 )
2016
24
Omega-3 fatty acids supplementation improves endothelial function and arterial stiffness in hypertensive patients with hypertriglyceridemia and high cardiovascular risk. ( 27876342 )
2016
25
Clinical features and treatment of hypertriglyceridemia-induced acute pancreatitis during pregnancy: A retrospective study. ( 26946248 )
2016
26
A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. ( 27981496 )
2016
27
PPARI+ Agonist Fenofibrate Reduced the Secreting Load of I^-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance. ( 27034649 )
2016
28
The Association Between Obesity and Cognitive Function in Older Persons: How Much Is Mediated by Inflammation, Fasting Plasma Glucose, and Hypertriglyceridemia? ( 27075896 )
2016
29
Hypertriglyceridemia: A simple approach to identify insulin resistance and enhanced cardio-metabolic risk in patients with prediabetes. ( 27565692 )
2016
30
Therapeutic plasma exchange for hypertriglyceridemia induced pancreatitis: A rapid and practical approach. ( 26947356 )
2016
31
Increased Serum Level of Cyclopropaneoctanoic Acid 2-Hexyl in Patients with Hypertriglyceridemia-Related Disorders. ( 27003900 )
2016
32
Differences in Severity and Outcomes Between Hypertriglyceridemia and Alcohol-Induced Pancreatitis. ( 27042605 )
2016
33
Plasmapheresis in pregnant patient with familial hypertriglyceridemia. ( 27095069 )
2016
34
Xanthoma disseminatum with extensive koebnerization associated with familial hypertriglyceridemia. ( 27437441 )
2016
35
Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice. ( 27226540 )
2016
36
Familial hypertriglyceridemia manifests with pancytopenia and bone marrow pseudoa89Niemann-Pick cells. ( 27453965 )
2016
37
Managing hypertriglyceridemia in children with systemic lupus erythematosus: Two sides of the same coin. ( 27717836 )
2016
38
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. ( 27919362 )
2016
39
Effect Of Hypertriglyceridemia, Sugar Ingestion, And Exercise On Substrate Metabolism In Overweight And Obese Individuals: 1900 Board #52 June 2, 3: 30 PM - 5: 00 PM. ( 27360725 )
2016
40
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. ( 27444154 )
2016
41
Frequency of rare mutations and common genetic variations in severe hypertriglyceridemia in the general population of Spain. ( 27108409 )
2016
42
Association of post-prandial hypertriglyceridemia a risk factor for macrovascular complications in type 2 diabetes mellitus. ( 27727603 )
2016
43
Lomitapide for the treatment of hypertriglyceridemia. ( 27785928 )
2016
44
Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. ( 27578119 )
2016
45
Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis. ( 27582413 )
2016
46
Hypertriglyceridemia-induced Acute Pancreatitis. ( 27876326 )
2016
47
Soy isoflavones (Glycine max) ameliorate hypertriglyceridemia and hepatic steatosis in high fat-fed ovariectomized Wistar rats (an experimental model of postmenopausal obesity). ( 27723468 )
2016
48
Olanzapine-Induced Hypertriglyceridemia Resulting in Necrotizing Pancreatitis. ( 27807566 )
2016
49
Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. ( 27424313 )
2016
50
Hypertriglyceridemia-induced acute pancreatitis in pregnancy causing maternal death. ( 27004207 )
2016

Variations for Hypertriglyceridemia

UniProtKB/Swiss-Prot genetic disease variations for Hypertriglyceridemia:

66
id Symbol AA change Variation ID SNP ID
1 LIPI p.Cys55Tyr VAR_023760 rs11909217

Expression for Hypertriglyceridemia

Search GEO for disease gene expression data for Hypertriglyceridemia.

Pathways for Hypertriglyceridemia

Pathways related to Hypertriglyceridemia according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 ADIPOQ APOA1 APOA2 APOA5 APOB APOC2
2
Show member pathways
12.73 ADIPOQ APOA1 APOA2 APOA5 GPD1 LPL
3
Show member pathways
12.58 APOA1 APOA2 APOB APOC2 APOC3 APOE
4
Show member pathways
12.3 APOA1 APOA2 APOA5 APOB APOC2 APOC3
5
Show member pathways
12.24 APOA1 APOB APOE INS LDLR SERPINE1
6
Show member pathways
12.09 APOA1 APOA2 APOB APOC2 APOC3 APOE
7 11.88 ADIPOQ INS LPL SERPINE1
8
Show member pathways
11.72 APOA1 APOB APOE
9 11.67 ADIPOQ INS LPL
10 11.59 ADIPOQ APOA1 APOA2 APOA5 APOC3 LPL
11 11.53 INS LDLR LPL
12
Show member pathways
11.2 APOA1 APOA2 APOA5 APOB APOC2 APOC3
13 11.12 APOA1 APOA2 APOA5 APOC3
14 10.82 APOA1 APOA2

GO Terms for Hypertriglyceridemia

Cellular components related to Hypertriglyceridemia according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.84 APOA1 APOA2 APOA5 APOE
2 chylomicron GO:0042627 9.76 APOA1 APOA2 APOA5 APOB APOC2 APOC3
3 spherical high-density lipoprotein particle GO:0034366 9.73 APOA1 APOA2 APOC2 APOC3
4 low-density lipoprotein particle GO:0034362 9.73 APOA1 APOA5 APOB APOC2 APOE LDLR
5 intermediate-density lipoprotein particle GO:0034363 9.72 APOA1 APOB APOC2 APOC3 APOE
6 clathrin-coated endocytic vesicle membrane GO:0030669 9.7 APOB APOE LDLR
7 endocytic vesicle lumen GO:0071682 9.67 APOA1 APOB APOE
8 very-low-density lipoprotein particle GO:0034361 9.56 APOA1 APOA2 APOA5 APOB APOC2 APOC3
9 endosome lumen GO:0031904 9.55 APOB INS
10 high-density lipoprotein particle GO:0034364 9.17 APOA1 APOA2 APOA5 APOC2 APOE CETP
11 extracellular region GO:0005576 10.28 ADIPOQ APOA1 APOA2 APOA5 APOB APOC2
12 extracellular exosome GO:0070062 10.25 ADIPOQ APOA1 APOA2 APOB APOC2 APOC3
13 extracellular space GO:0005615 10.21 ADIPOQ APOA1 APOA2 APOA5 APOB APOC2
14 endoplasmic reticulum lumen GO:0005788 10.02 APOA1 APOA2 APOA5 APOB APOE INS
15 early endosome GO:0005769 10 APOA1 APOA2 APOB APOC2 APOC3 APOE

Biological processes related to Hypertriglyceridemia according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
id Name GO ID Score Top Affiliating Genes
1 phospholipid efflux GO:0033700 9.99 APOA1 APOA2 APOA5 APOC2 APOC3 APOE
2 chylomicron assembly GO:0034378 9.97 APOA1 APOA2 APOB APOC2 APOC3 APOE
3 very-low-density lipoprotein particle remodeling GO:0034372 9.93 APOC2 APOE CETP LIPC LPL
4 positive regulation of catalytic activity GO:0043085 9.92 APOA2 APOC2 APOE
5 regulation of lipid metabolic process GO:0019216 9.92 APOA1 APOA2 APOA5
6 reverse cholesterol transport GO:0043691 9.92 APOA1 APOA2 APOA5 APOC2 APOC3 APOE
7 negative regulation of inflammatory response GO:0050728 9.91 ADIPOQ APOA1 APOE
8 high-density lipoprotein particle assembly GO:0034380 9.91 APOA1 APOA2 APOA5 APOE
9 lipoprotein biosynthetic process GO:0042158 9.91 APOA1 APOA2 APOB APOE
10 response to glucose GO:0009749 9.9 ADIPOQ APOA2 LPL
11 positive regulation of cholesterol esterification GO:0010873 9.9 APOA1 APOA2 APOA5 APOE
12 positive regulation of inflammatory response GO:0050729 9.89 LDLR LPL SERPINE1
13 high-density lipoprotein particle clearance GO:0034384 9.89 APOA1 APOA2 APOC2 APOE
14 phospholipid transport GO:0015914 9.87 APOA1 CETP LDLR
15 triglyceride homeostasis GO:0070328 9.86 APOA1 APOA5 APOC2 APOC3 APOE CETP
16 low-density lipoprotein particle clearance GO:0034383 9.85 ADIPOQ APOB LDLR
17 negative regulation of lipid catabolic process GO:0050995 9.85 APOA2 APOC3 INS
18 positive regulation of fatty acid biosynthetic process GO:0045723 9.85 APOA1 APOA5 APOC2
19 positive regulation of lipoprotein lipase activity GO:0051006 9.84 APOA1 APOA5 APOC2
20 positive regulation of triglyceride catabolic process GO:0010898 9.84 APOA1 APOA5 APOC2
21 neuron projection regeneration GO:0031102 9.83 APOA1 APOA5 APOE
22 regulation of Cdc42 protein signal transduction GO:0032489 9.82 APOA1 APOC3 APOE
23 regulation of intestinal cholesterol absorption GO:0030300 9.82 APOA1 APOA2 APOA5
24 lipoprotein catabolic process GO:0042159 9.81 APOB APOE LDLR
25 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.8 APOA1 APOA2 APOC3
26 triglyceride-rich lipoprotein particle remodeling GO:0034370 9.8 APOA2 APOA5 APOC2
27 positive regulation of receptor-mediated endocytosis GO:0048260 9.76 APOA5 SERPINE1
28 positive regulation of nitric-oxide synthase activity GO:0051000 9.76 APOE INS
29 negative regulation of tumor necrosis factor-mediated signaling pathway GO:0010804 9.76 ADIPOQ APOA1
30 positive regulation of cellular protein metabolic process GO:0032270 9.75 ADIPOQ INS
31 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.75 APOB LPL
32 lipoprotein transport GO:0042953 9.75 APOB APOC2
33 positive regulation of cholesterol efflux GO:0010875 9.75 ADIPOQ APOE
34 positive regulation of glycolytic process GO:0045821 9.75 GPD1 INS
35 negative regulation of gluconeogenesis GO:0045721 9.75 ADIPOQ INS
36 lipid digestion GO:0044241 9.75 LIPC LIPI
37 negative regulation of smooth muscle cell migration GO:0014912 9.74 ADIPOQ SERPINE1
38 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.74 ADIPOQ CETP
39 negative regulation of blood coagulation GO:0030195 9.74 APOE SERPINE1
40 fatty acid homeostasis GO:0055089 9.74 APOE INS
41 phosphatidylcholine metabolic process GO:0046470 9.74 APOA5 CETP
42 positive regulation of lipid biosynthetic process GO:0046889 9.73 APOE INS
43 very-low-density lipoprotein particle assembly GO:0034379 9.73 APOB APOC3
44 regulation of lipoprotein lipase activity GO:0051004 9.73 LIPC LPL
45 phospholipid homeostasis GO:0055091 9.73 APOA1 CETP
46 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.72 ADIPOQ APOA1
47 positive regulation of cholesterol storage GO:0010886 9.72 APOB LPL
48 negative regulation of receptor-mediated endocytosis GO:0048261 9.72 APOC2 APOC3
49 positive regulation of lipid catabolic process GO:0050996 9.72 APOA2 APOA5
50 negative regulation of cytokine secretion involved in immune response GO:0002740 9.71 APOA1 APOA2

Molecular functions related to Hypertriglyceridemia according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.91 APOA1 APOA2 APOA5 APOB APOC3 APOE
2 heparin binding GO:0008201 9.91 APOA5 APOB APOE LIPC LIPI LPA
3 phosphatidylcholine binding GO:0031210 9.78 APOA1 APOA2 APOA5 CETP
4 protease binding GO:0002020 9.77 INS LDLR SERPINE1
5 carboxylic ester hydrolase activity GO:0052689 9.74 LIPC LIPI LPL
6 low-density lipoprotein particle receptor binding GO:0050750 9.7 APOA5 APOB APOE
7 apolipoprotein binding GO:0034185 9.69 LIPC LPA LPL
8 phospholipase activity GO:0004620 9.67 LIPC LIPI LPL
9 high-density lipoprotein particle receptor binding GO:0070653 9.63 APOA1 APOA2 APOC3
10 triglyceride lipase activity GO:0004806 9.62 LIPC LPL
11 lipase inhibitor activity GO:0055102 9.62 APOA1 APOA2 APOC2 APOC3
12 phospholipid transporter activity GO:0005548 9.61 APOA1 CETP
13 low-density lipoprotein particle binding GO:0030169 9.61 LDLR LIPC
14 high-density lipoprotein particle binding GO:0008035 9.59 APOA1 APOA2
15 lipase binding GO:0035473 9.58 APOA5 APOB
16 lipoprotein particle binding GO:0071813 9.58 APOA1 APOE
17 apolipoprotein receptor binding GO:0034190 9.56 APOA1 APOA2
18 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.56 APOA1 APOA2 APOA5 APOE
19 lipoprotein lipase activator activity GO:0060230 9.55 APOA5 APOC2
20 lipid transporter activity GO:0005319 9.55 APOA1 APOA2 APOB APOE CETP
21 triglyceride binding GO:0017129 9.54 CETP LPL
22 cholesterol binding GO:0015485 9.43 APOA1 APOA2 APOA5 APOC3 APOE CETP
23 cholesterol transporter activity GO:0017127 9.1 APOA1 APOA2 APOA5 APOB APOE CETP
24 lipid binding GO:0008289 10.01 APOA1 APOA2 APOA5 APOB APOC2 APOC3

Sources for Hypertriglyceridemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....